JP2010525044A - 筋肉減少の治療に使用される薬剤の組合せ - Google Patents
筋肉減少の治療に使用される薬剤の組合せ Download PDFInfo
- Publication number
- JP2010525044A JP2010525044A JP2010504834A JP2010504834A JP2010525044A JP 2010525044 A JP2010525044 A JP 2010525044A JP 2010504834 A JP2010504834 A JP 2010504834A JP 2010504834 A JP2010504834 A JP 2010504834A JP 2010525044 A JP2010525044 A JP 2010525044A
- Authority
- JP
- Japan
- Prior art keywords
- product
- ritodrine
- agonist
- muscle loss
- formoterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Immunology (AREA)
Abstract
Description
当研究は、悪液質の確立に係わる機構の研究に特に適したモデル系であるヨシダAH-130ラット腹水肝細胞癌の使用に関する。その増殖は宿主における(特に骨格筋における)急速で進行性の体重減少及び組織消耗を引き起こす。当該研究はβ2アゴニストであるラセミのフォルモテロール、R,R-フォルモテロール、ラセミのリトドリン、単一エナンチオマーの(-)-リトドリン及びインダカテロールの、腫瘍によって引き起こされた組織消耗に対する効果を検討する。これらのβ2アゴニスト各々とプロゲスチン、酢酸メゲストロールとの同時投与も調査される。
Claims (32)
- β2アゴニスト及びプロゲスチンを含む産物であって、筋肉減少の治療又は予防において別々に、同時に、又は順次的に使用されるための、組合せ調製物としての、産物。
- プロゲスチンがメゲストロールである、請求項1に記載の産物。
- メゲストロールが酢酸塩である、請求項2に記載の産物。
- プロゲスチンが酢酸メドロキシプロゲステロンである、請求項1に記載の産物。
- β2アゴニストがフォルモテロールである、請求項1〜4のいずれかに記載の産物。
- フォルモテロールがR,R-フォルモテロールである、請求5に記載の産物。
- β2アゴニストがリトドリンである、請求項1〜4のいずれかに記載の産物。
- リトドリンが実質的に単一エナンチオマーの(-)-リトドリンである、請求項7に記載の産物。
- β2アゴニストがインダカテロールである、請求項1〜4のいずれかに記載の産物。
- R,R-フォルモテロール、インダカテロール又はリトドリンから選択されるβ2アゴニストを含む、筋肉減少の治療又は予防に使用するための産物。
- リトドリンが実質的に単一エナンチオマーの(-)-リトドリンである、請求項10に記載の産物。
- 筋肉減少が癌性悪液質に連関したものである、請求項1〜11のいずれかに記載の産物。
- 筋肉減少がCOPDに連関したものである、請求項1〜11のいずれかに記載の産物。
- 筋肉減少がジストロフィーに連関したものである、請求項1〜11のいずれかに記載の産物。
- 筋肉減少がCHFに連関したものである、請求項1〜11のいずれかに記載の産物。
- 筋肉減少がAIDSに連関したものである、請求項1〜11のいずれかに記載の産物。
- 筋肉減少が火傷に連関したものである、請求項1〜11のいずれかに記載の産物。
- マクロライドを含まない、請求項1〜17のいずれかに記載の産物。
- 経口投与のための、請求項1〜18のいずれかに記載の産物。
- 副腎皮質ステロイドを付加的に含む、請求項1〜19のいずれかに記載の産物。
- カンナビノイドを付加的に含む、請求項1〜20のいずれかに記載の産物。
- 筋肉減少の治療又は予防に使用するための、β2アゴニストを含む医薬であって、当該処置の対象がプロゲスチンによる処置も受ける場合における、医薬。
- 筋肉減少の治療又は予防に使用するための、プロゲスチンを含む医薬であって、当該処置の対象がβ2アゴニストによる処置も受ける場合における、医薬。
- プロゲスチンがメゲストロールである、請求項22又は23に記載の医薬。
- メゲストロールが酢酸塩である、請求項24に記載の医薬。
- プロゲスチンが酢酸メドロキシプロゲステロンである、請求項22又は23に記載の医薬。
- R,R-フォルモテロール、インダカテロール又はリトドリンから選択されるβ2アゴニストを含む医薬であって、筋肉減少の治療又は予防に使用するための医薬。
- リトドリンが実質的に単一エナンチオマーの(-)-リトドリンである、請求項27に記載の医薬。
- 筋肉減少が癌性悪液質、COPD、ジストロフィー、火傷、CHF又はAIDSに連関したものである、請求項22〜28のいずれかに記載の医薬。
- 経口的に投与される、請求項22〜29のいずれかに記載の医薬。
- 請求項22〜30のいずれかに記載の医薬であって、当該処置の対象が副腎皮質ステロイドによる処置も受ける場合における、医薬。
- 請求項22〜31のいずれかに記載の医薬であって、当該処置の対象がカンナビノイドによる処置も受ける場合における、医薬。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707930A GB0707930D0 (en) | 2007-04-24 | 2007-04-24 | New therapeutic use |
GB0707931.2 | 2007-04-24 | ||
GB0707930.4 | 2007-04-24 | ||
GB0707931A GB0707931D0 (en) | 2007-04-24 | 2007-04-24 | New Therapeutic use |
GB0710101.7 | 2007-05-25 | ||
GB0710101A GB0710101D0 (en) | 2007-05-25 | 2007-05-25 | New Therapeutic use |
PCT/GB2008/001452 WO2008129308A2 (en) | 2007-04-24 | 2008-04-24 | Drug combination and its use in the treatment of muscle loss |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010525044A true JP2010525044A (ja) | 2010-07-22 |
JP2010525044A5 JP2010525044A5 (ja) | 2011-05-06 |
JP5627452B2 JP5627452B2 (ja) | 2014-11-19 |
Family
ID=39639100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010504834A Expired - Fee Related JP5627452B2 (ja) | 2007-04-24 | 2008-04-24 | 筋肉減少の治療に使用される薬剤の組合せ |
Country Status (16)
Country | Link |
---|---|
US (1) | US8653052B2 (ja) |
EP (1) | EP2155180B1 (ja) |
JP (1) | JP5627452B2 (ja) |
KR (1) | KR101546977B1 (ja) |
CN (2) | CN101730547A (ja) |
AU (1) | AU2008240379B2 (ja) |
BR (1) | BRPI0810461A2 (ja) |
CA (1) | CA2721739C (ja) |
DK (1) | DK2155180T3 (ja) |
EA (1) | EA018918B1 (ja) |
ES (1) | ES2592289T3 (ja) |
HK (1) | HK1202262A1 (ja) |
IL (1) | IL201426A (ja) |
MX (1) | MX2009011294A (ja) |
NZ (1) | NZ580975A (ja) |
WO (1) | WO2008129308A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013543897A (ja) * | 2010-11-24 | 2013-12-09 | リセラ,インク. | 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法 |
US9452147B2 (en) | 2005-07-14 | 2016-09-27 | Neothetics, Inc. | Lipolytic methods |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021509A2 (en) | 1998-10-15 | 2000-04-20 | Imperial College Innovations Limited | Methods of treatment |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
KR101980180B1 (ko) * | 2014-08-05 | 2019-05-20 | 라퀄리아 파마 인코포레이티드 | 그렐린 수용체 작용제로서의 세린 유도체 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527584A (ja) * | 2002-04-12 | 2005-09-15 | エラン ファーマ インターナショナル,リミティド | ナノ粒子メゲストロール製剤 |
WO2006003222A1 (es) * | 2004-06-29 | 2006-01-12 | Universidad De Barcelona | Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras |
JP2006510726A (ja) * | 2002-12-03 | 2006-03-30 | エラン ファーマ インターナショナル リミテッド | 低粘度液体剤形 |
WO2007095497A2 (en) * | 2006-02-13 | 2007-08-23 | Anaborex Inc. | Compositions and methods for prevention and treatment of cachexia |
WO2008093148A2 (en) * | 2005-12-22 | 2008-08-07 | Anaborex, Inc. | Compositions and methods for prevention and treatment of cachexia |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308157B1 (en) | 1987-09-15 | 1997-02-26 | The Rowett Research Institute | Therapeutic applications of beta-adrenergic agonists |
-
2008
- 2008-04-24 AU AU2008240379A patent/AU2008240379B2/en not_active Ceased
- 2008-04-24 CN CN200880012990A patent/CN101730547A/zh active Pending
- 2008-04-24 CN CN201410490740.8A patent/CN104306381A/zh active Pending
- 2008-04-24 KR KR1020097024247A patent/KR101546977B1/ko not_active IP Right Cessation
- 2008-04-24 CA CA2721739A patent/CA2721739C/en not_active Expired - Fee Related
- 2008-04-24 WO PCT/GB2008/001452 patent/WO2008129308A2/en active Application Filing
- 2008-04-24 JP JP2010504834A patent/JP5627452B2/ja not_active Expired - Fee Related
- 2008-04-24 NZ NZ580975A patent/NZ580975A/xx not_active IP Right Cessation
- 2008-04-24 MX MX2009011294A patent/MX2009011294A/es active IP Right Grant
- 2008-04-24 BR BRPI0810461-1A2A patent/BRPI0810461A2/pt not_active IP Right Cessation
- 2008-04-24 US US12/594,985 patent/US8653052B2/en not_active Expired - Fee Related
- 2008-04-24 ES ES08737103.5T patent/ES2592289T3/es active Active
- 2008-04-24 DK DK08737103.5T patent/DK2155180T3/en active
- 2008-04-24 EP EP08737103.5A patent/EP2155180B1/en not_active Not-in-force
- 2008-04-24 EA EA200970957A patent/EA018918B1/ru not_active IP Right Cessation
-
2009
- 2009-10-11 IL IL201426A patent/IL201426A/en not_active IP Right Cessation
-
2015
- 2015-03-19 HK HK15102807.2A patent/HK1202262A1/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527584A (ja) * | 2002-04-12 | 2005-09-15 | エラン ファーマ インターナショナル,リミティド | ナノ粒子メゲストロール製剤 |
JP2006510726A (ja) * | 2002-12-03 | 2006-03-30 | エラン ファーマ インターナショナル リミテッド | 低粘度液体剤形 |
WO2006003222A1 (es) * | 2004-06-29 | 2006-01-12 | Universidad De Barcelona | Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras |
WO2008093148A2 (en) * | 2005-12-22 | 2008-08-07 | Anaborex, Inc. | Compositions and methods for prevention and treatment of cachexia |
WO2007095497A2 (en) * | 2006-02-13 | 2007-08-23 | Anaborex Inc. | Compositions and methods for prevention and treatment of cachexia |
Non-Patent Citations (7)
Title |
---|
JPN6014003936; Joseph M. Argiles et al.: 'The Pharmacological Treatment of Cachexia' Current Drug Targets Vol. 5, No. 3, 20040401, 265-277 * |
JPN6014003937; M. Tomiska et al.: 'Palliative treatment of cancer anorexia with aral suspension of megestrol acetate' NEAOPLASMA Vol. 50, No. 3, 20030101, 227-233 * |
JPN6014003939; Francisco Gomez et al.: 'Treatment with Megestrol Acetate Improves Human Immunodeficiency Virus-Associated Immune Thrombocyto' Clinical and Diagnostic Laboratory Immunology Vol. 9, No. 3, 20020501, 583-587 * |
JPN6014003940; G. Mantovani et al.: 'Medroxyprogesterone Acetate Reduces the In Vitro Production of Cytokines and Serotonin Involved in A' European Journal of Cancer Vol. 33, No. 4, 19970401, 602-607 * |
JPN6014003942; James G. Ryall et al.: 'Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal mus' British Journal of Pharmacology Vol. 147, No. 6, 200603, 587-595 * |
JPN6014003945; Silvia Busquets et al.: 'Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting' Cancer Research Vol. 64, 20040915, 6725-6731 * |
JPN6014003948; Leah J. Harcourt et al.: 'Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasin' Neuromuscular Disorders Vol. 17,No. 1, 20070202, 47-55 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9452147B2 (en) | 2005-07-14 | 2016-09-27 | Neothetics, Inc. | Lipolytic methods |
US9707192B2 (en) | 2005-07-14 | 2017-07-18 | Neothetics, Inc. | Lipolytic methods |
JP2013543897A (ja) * | 2010-11-24 | 2013-12-09 | リセラ,インク. | 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法 |
US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
Also Published As
Publication number | Publication date |
---|---|
HK1202262A1 (en) | 2015-09-25 |
DK2155180T3 (en) | 2016-09-12 |
IL201426A (en) | 2016-09-29 |
AU2008240379A1 (en) | 2008-10-30 |
CA2721739A1 (en) | 2008-10-30 |
KR101546977B1 (ko) | 2015-08-24 |
IL201426A0 (en) | 2010-05-31 |
US8653052B2 (en) | 2014-02-18 |
ES2592289T3 (es) | 2016-11-29 |
EP2155180A2 (en) | 2010-02-24 |
MX2009011294A (es) | 2010-01-29 |
KR20100017205A (ko) | 2010-02-16 |
BRPI0810461A2 (pt) | 2014-10-14 |
WO2008129308A2 (en) | 2008-10-30 |
CN101730547A (zh) | 2010-06-09 |
US20100130456A1 (en) | 2010-05-27 |
EP2155180B1 (en) | 2016-07-13 |
WO2008129308A3 (en) | 2009-12-17 |
EA200970957A1 (ru) | 2010-04-30 |
NZ580975A (en) | 2012-10-26 |
CN104306381A (zh) | 2015-01-28 |
EA018918B1 (ru) | 2013-11-29 |
JP5627452B2 (ja) | 2014-11-19 |
AU2008240379B2 (en) | 2012-10-04 |
CA2721739C (en) | 2016-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI434688B (zh) | 選擇性s1p1受體激動劑之投藥療程 | |
RU2617502C2 (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
JP5627452B2 (ja) | 筋肉減少の治療に使用される薬剤の組合せ | |
JP2002226401A (ja) | うつ病の併用療法 | |
JP2023030091A (ja) | ポネシモドを含有する医薬的組み合わせ | |
CA2671622C (en) | Treatment of cachexia | |
CA2811345A1 (en) | Compound composition for inhalation used for treating asthma | |
KR102266696B1 (ko) | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 | |
KR20180119597A (ko) | 염증 상태의 급성 악화의 치료를 위한 투약법 | |
JP7033454B2 (ja) | Aerd/喘息におけるトロンボキサン受容体拮抗薬 | |
JP5469779B2 (ja) | 多発性骨髄腫の治療のための組成物および方法 | |
JP2021534141A (ja) | アルコール使用障害の治療剤 | |
RU2569732C9 (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110317 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140428 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140604 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140611 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140613 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140918 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140930 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5627452 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |